Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Cash (2016 - 2025)

Historic Change in Cash for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.9 million.

  • CytomX Therapeutics' Change in Cash fell 48008.59% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 14358.2%. This contributed to the annual value of $21.0 million for FY2024, which is 11189.43% up from last year.
  • Per CytomX Therapeutics' latest filing, its Change in Cash stood at -$14.9 million for Q3 2025, which was down 48008.59% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Cash ranged from a high of $137.8 million in Q1 2021 and a low of -$137.3 million during Q1 2023
  • Over the past 5 years, CytomX Therapeutics' median Change in Cash value was -$8.9 million (recorded in 2023), while the average stood at -$8.3 million.
  • As far as peak fluctuations go, CytomX Therapeutics' Change in Cash soared by 49898.22% in 2024, and later plummeted by 48008.59% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Change in Cash stood at -$30.8 million in 2021, then soared by 420.66% to $98.6 million in 2022, then plummeted by 108.98% to -$8.9 million in 2023, then soared by 71.49% to -$2.5 million in 2024, then tumbled by 488.59% to -$14.9 million in 2025.
  • Its Change in Cash stands at -$14.9 million for Q3 2025, versus $1.4 million for Q2 2025 and $9.6 million for Q1 2025.